Positive News SentimentPositive News Syros Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SYRS) $2.65 -0.10 (-3.64%) (As of 02:30 PM ET) Add Compare Share Share Today's Range$2.52▼$2.8550-Day Range$2.13▼$4.0052-Week Range$2.09▼$5.67Volume65,650 shsAverage Volume86,408 shsMarket Capitalization$55.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside363.0% Upside$12.50 Price TargetShort InterestHealthy2.99% of Float Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.78) to ($4.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.51 out of 5 starsMedical Sector151st out of 948 stocksPharmaceutical Preparations Industry59th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Syros Pharmaceuticals has a forecasted upside of 363.0% from its current price of $2.70.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.99% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 11.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 68.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.57. Previous Next 3.3 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search Interest7 people have searched for SYRS on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.29% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($4.78) to ($4.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syros Pharmaceuticals Stock (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesNovember 16, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)November 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and Kiora Pharmaceuticals (KPRX)December 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 15, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | markets.businessinsider.comSyros Pharmaceuticals Q3 Loss misses estimatesNovember 14, 2023 | finance.yahoo.comSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNovember 13, 2023 | benzinga.comPreview: Syros Pharmaceuticals's EarningsNovember 12, 2023 | morningstar.comSyros Pharmaceuticals Inc SYRSDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023October 4, 2023 | bizjournals.comSyros CEO, chief scientist out as company cuts staff, programsOctober 3, 2023 | marketwatch.comSyros Pharmaceuticals Shares Fall 18% on Staff Cuts, CEO RetirementOctober 2, 2023 | marketwatch.comSyros Pharmaceuticals to Cut 35% of Staff; CEO Simonian to RetireOctober 2, 2023 | finance.yahoo.comSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical CompanyAugust 10, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)August 9, 2023 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) Gets a Buy from H.C. WainwrightAugust 9, 2023 | finance.yahoo.comQ2 2023 Syros Pharmaceuticals Inc Earnings CallAugust 8, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAugust 1, 2023 | finance.yahoo.comSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023July 24, 2023 | benzinga.comPfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood DisordersJuly 21, 2023 | finance.yahoo.comPfizer to end license deal with Syros for blood disorder therapiesJuly 6, 2023 | msn.comSyros Pharmaceuticals (SYRS) Price Target Increased by 22.53% to 164.73June 8, 2023 | finance.yahoo.comSyros to Present at Sidoti June 2023 Virtual Small-Cap ConferenceMay 25, 2023 | finance.yahoo.comSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual MeetingMay 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous YearMay 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \See More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2021Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees117Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+363.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,650,000.00 Net MarginsN/A Pretax Margin-1,193.45% Return on Equity-155.06% Return on Assets-68.52% Debt Debt-to-Equity Ratio1.09 Current Ratio4.31 Quick Ratio4.31 Sales & Book Value Annual Sales$14.88 million Price / Sales3.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book1.57Miscellaneous Outstanding Shares21,070,000Free Float18,865,000Market Cap$56.89 million OptionableOptionable Beta1.46 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Nancy A. Simonian M.D. (Age 62)President, CEO & Director Comp: $955.39kDr. Richard A. Young Ph.D. (Age 69)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $108.37kDr. David A. Roth M.D. (Age 60)Chief Medical Officer Comp: $679.52kDr. James E. Bradner M.D. (Age 51)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Jason Haas (Age 55)Chief Financial Officer Comp: $457.22kMs. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 55)J.D., Chief Legal & Compliance Officer Comp: $127.07kMs. Lisa RobertsVice President of Human ResourcesMs. Kristin Stephens (Age 50)Chief Development Officer More ExecutivesKey CompetitorsCoya TherapeuticsNASDAQ:COYAAnebulo PharmaceuticalsNASDAQ:ANEBRockwell MedicalNASDAQ:RMTIMIRA PharmaceuticalsNASDAQ:MIRAVYNE TherapeuticsNASDAQ:VYNEView All CompetitorsInsiders & InstitutionsAvidity Partners Management LPBought 117,108 shares on 11/14/2023Ownership: 7.635%CHI Advisors LLCBought 531,914 shares on 11/13/2023Ownership: 6.274%LPL Financial LLCSold 3,900 shares on 11/13/2023Ownership: 0.435%Assenagon Asset Management S.A.Bought 14,754 shares on 11/6/2023Ownership: 0.121%Clarius Group LLCBought 18,620 shares on 10/19/2023Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions SYRS Stock Analysis - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price target for 2024? 4 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' shares. Their SYRS share price targets range from $7.00 to $15.00. On average, they expect the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 363.0% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2023? Syros Pharmaceuticals' stock was trading at $3.59 at the start of the year. Since then, SYRS shares have decreased by 24.8% and is now trading at $2.70. View the best growth stocks for 2023 here. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.40) by $0.30. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. During the same period in the previous year, the company posted ($4.30) earnings per share. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals's stock reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (7.63%), CHI Advisors LLC (6.27%), LPL Financial LLC (0.44%), Assenagon Asset Management S.A. (0.12%), Clarius Group LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Roth, Eric R Olson, Richard A Young and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SYRS) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.